Ablynx, a Sanofi company

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Ablynx, a Sanofi company sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 9 completed early-phase tilt top decile by trial count

Ablynx, a Sanofi company: 9 sponsored US clinical trials, none currently recruiting.

Ablynx, a Sanofi company sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 1 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Active Rheumatoid Arthritis, with 1 trials.

Top-decile sponsor footprint

Ablynx, a Sanofi company ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

COMPLETED Phase 1

Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.

NCT03172208
COMPLETED Phase 3

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

NCT02553317
COMPLETED Phase 2

A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus

NCT02437890
COMPLETED Phase 2

A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis

NCT02287922
COMPLETED Phase 2

A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis

NCT02309359
COMPLETED Phase 2

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT01151423
COMPLETED Phase 1

A Single Dose Study Of The Safety And Investigational Product Level Measurement In Healthy Subjects

NCT01284036
COMPLETED Phase 2

Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis

NCT01063803
COMPLETED Phase 1

Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis

NCT00959036

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 5
Phase 3 1

Therapeutic Areas

Active Rheumatoid Arthritis 1
Acquired Thrombotic Thrombocytopenic Purpura 1
Healthy Volunteers 1
Rheumatoid Arthritis 1

How the Ablynx, a Sanofi company early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 9 completed (100%).

Phase mix: 1 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Active Rheumatoid Arthritis (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Ablynx, a Sanofi company: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Ablynx, a Sanofi company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Ablynx, a Sanofi company4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAcacia Pharma10xBio22nd Century Group23andMe3-C Institute for Social Development
Ablynx, a Sanofi company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Ablynx, a Sanofi company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Ablynx, a Sanofi company page

9 registered trials is a research-attention snapshot, not an endorsement of Ablynx, a Sanofi company or any single study.

  • None of Ablynx, a Sanofi company's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Active Rheumatoid Arthritis is the condition Ablynx, a Sanofi company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Active Rheumatoid Arthritis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Ablynx, a Sanofi company pipeline card: 9 registered trials from official public datasets.Report a data error.